We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals
RYTM

87 hedge funds and large institutions have $846M invested in Rhythm Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 4

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

18% more funds holding

Funds holding: 74 → 87 (+13)

16% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 25

1% less capital invested

Capital invested by funds: $851M → $846M (-$4.87M)

2.35% less ownership

Funds ownership: 92% → 89.65% (-2.4%)

Holders
87
Holders Change
+13
Holders Change %
+17.57%
% of All Funds
1.88%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.13%
New
17
Increased
29
Reduced
25
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$6.15M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$2M
3
HP
Harbourvest Partners
Massachusetts
+$1.44M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.26M
5
SIM
Spark Investment Management
New York
+$1.11M

Top Sellers

Rank Fund Capital Flow
1
TG
TRV GP
Massachusetts
-$28.7M
2
O
OrbiMed
New York
-$4.06M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.89M
4
RCM
RA Capital Management
Massachusetts
-$1.88M
5
Citigroup
Citigroup
New York
-$1.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$2.68M +$1.26M +43,787 +81%
AA
27
ALPS Advisors
Colorado
$2.28M +$103K +3,594 +5%
EU
28
Emory University
Georgia
$2.18M -$96.8K -3,369 -4%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$1.91M +$70.8K +2,464 +4%
HP
30
Harbourvest Partners
Massachusetts
$1.38M +$1.44M +50,221 New
TOPU
31
Trustees of Princeton University
New Jersey
$1.31M – – –
Goldman Sachs
32
Goldman Sachs
New York
$1.29M +$774K +26,935 +134%
SIM
33
Spark Investment Management
New York
$1.06M +$1.11M +38,685 New
Russell Investments Group
34
Russell Investments Group
United Kingdom
$1.04M +$91.7K +3,192 +9%
HLA
35
Hamilton Lane Advisors
Pennsylvania
$952K +$998K +34,736 New
TA
36
Teachers Advisors
New York
$930K +$81K +2,820 +9%
FI
37
Fosun International
China
$887K – – –
Swiss National Bank
38
Swiss National Bank
Switzerland
$858K +$31.6K +1,100 +4%
ClearBridge Investments
39
ClearBridge Investments
New York
$844K +$86 +3 +0%
TCIM
40
TIAA CREF Investment Management
New York
$724K – – –
Squarepoint
41
Squarepoint
New York
$711K -$155K -5,392 -17%
Adage Capital Partners
42
Adage Capital Partners
Massachusetts
$685K +$718K +25,000 New
TCM
43
Tekla Capital Management
Massachusetts
$682K – – –
PPA
44
Parametric Portfolio Associates
Washington
$642K -$166K -5,770 -20%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$639K -$5.32K -185 -0.8%
RHJA
46
Rice Hall James & Associates
California
$636K +$667K +23,202 New
Aberdeen Group
47
Aberdeen Group
United Kingdom
$590K +$619K +21,523 New
State of Wisconsin Investment Board
48
State of Wisconsin Investment Board
Wisconsin
$565K +$138K +4,800 +30%
Bank of America
49
Bank of America
North Carolina
$541K -$185K -6,434 -25%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$537K +$1.44K +50 +0.3%
1
2
3 4

RYTM Hedge Fund Activity: Q1 2019 in Review

87 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2019, worth a combined $846M — down 0.57% from $851M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RYTM positions and 4 closed out — a net gain of 13 holders — while 29 added to existing stakes and 25 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $6.15M. The largest seller was TRV GP, cutting an estimated $28.7M.

  • 87 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2019, up from 74 in Q4 2018.
  • Funds reported $846M of Rhythm Pharmaceuticals stock for Q1 2019, down 0.57% quarter-over-quarter.
  • 17 funds opened new Rhythm Pharmaceuticals positions in Q1 2019 and 4 closed out, a net change of +13 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q1 2019 was T. Rowe Price Associates, an estimated $6.15M added.
  • The largest Rhythm Pharmaceuticals seller in Q1 2019 was TRV GP, an estimated $28.7M sold.

Based on aggregated 13F filings for Q1 2019.